Overview

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease Dementia

Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease dementia. The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with Alzheimer's Disease dementia treated with KarXT compared to placebo. The secondary objectives of the study are to evaluate the time from randomization to discontinuation for any reason and safety and tolerability in subjects with psychosis associated with Alzheimer's Disease dementia treated with KarXT compared to placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Karuna Therapeutics